Diagnosis of Basal-Like Breast Cancer Using a FOXC1-Based Assay
Authors:
- Tor W. JensenTJTor W. Jensen
- Tania RayTRTania Ray
- Jinhua WangJWJinhua Wang
- Xiaodong LiXLXiaodong Li
- Wesley Y. NaritokuWNWesley Y. Naritoku
- Bingchen HanBHBingchen Han
- Frank BellafioreFBFrank Bellafiore
- Sanjay P. BagariaSBSanjay P. Bagaria
- Annie QuAQAnnie Qu
- Xiaojiang CuiXCXiaojiang Cui
- Clive R. TaylorCTClive R. Taylor
- Partha S. RayPRPartha S. Ray
Open Access
- 3 June 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 107 (8)
Abstract
Diagnosis of basal-like breast cancer (BLBC) remains a bottleneck to conducting effective clinical trials for this aggressive subtype. We postulated that elevated expression of Forkhead Box transcription factor C1 (FOXC1) is a simple and accurate diagnostic biomarker for BLBC. Accuracy of FOXC1 expression in identifying BLBC was compared with the PAM50 gene expression panel in gene expression microarray (GEM) (n = 1992) and quantitative real-time polymerase chain reaction (qRT-PCR) (n = 349) datasets. A FOXC1-based immunohistochemical (IHC) assay was developed and assessed in 96 archival formalin-fixed, paraffin-embedded (FFPE) breast cancer samples that also underwent PAM50 profiling. All statistical tests were two-sided. A FOXC1-based two-tier assay (IHC +/- qRT-PCR) accurately identified BLBC (AUC = 0.88) in an independent cohort of FFPE samples, validating the accuracy of FOXC1-defined BLBC in GEM (AUC = 0.90) and qRT-PCR (AUC = 0.88) studies, when compared with platform-specific PAM50-defined BLBC. The hazard ratio (HR) for disease-specific survival in patients having FOXC1-defined BLBC was 1.71 (95% CI = 1.31 to 2.23, P < .001), comparable to PAM50 assay-defined BLBC (HR = 1.74, 95% CI = 1.40 to 2.17, P < .001). FOXC1 expression also predicted the development of brain metastasis. Importantly, unlike triple-negative or Core Basal IHC definitions, a FOXC1-based definition is able to identify BLBC in both ER+ and HER2+ patients. A FOXC1-based two-tier assay, by virtue of being rapid, simple, accurate, and cost-effective may emerge as the diagnostic assay of choice for BLBC. Such a test could substantially improve clinical trial enrichment of BLBC patients and accelerate the identification of effective chemotherapeutic options for this aggressive disease.Keywords
This publication has 29 references indexed in Scilit:
- A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standardLaboratory Investigation, 2013
- Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profilesLaboratory Investigation, 2013
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast CarcinomaClinical Cancer Research, 2004
- Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD InitiativeAnnals of Internal Medicine, 2003
- The STARD initiativeThe Lancet, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- Molecular portraits of human breast tumoursNature, 2000
- A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samplesHuman Pathology, 1995
- ESTROGEN-RECEPTOR ANALYSES - CORRELATION OF BIOCHEMICAL AND IMMUNOHISTOCHEMICAL METHODS USING MONOCLONAL ANTIRECEPTOR ANTIBODIES1985